Skip to main content
  • Register
  • Help
  • Contact us
  • Log in to HL Account

Travere Therapeutics Inc (TVTX) USD0.0001

Sell:$24.07 Buy:$25.74 Change: No change
Prices delayed by at least 15 minutes | Switch to live prices |
Change: No change
Prices delayed by at least 15 minutes | Switch to live prices |
Change: No change
Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Travere Therapeutics Inc., formerly Retrophin Inc., is a biopharmaceutical company. The Company specializing in identifying, developing and delivering therapies to people living with rare disease. It's pipeline includes sparsentan (RE-021), a product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN). Sparsentan is an investigational product candidate with a dual mechanism of action, selective endothelin receptor antagonist (ERA), with in vitro selectivity toward endothelin receptor type A and a potent angiotensin receptor blocker (ARB). It's pipeline also includes also include OT-58, an investigational human enzyme replacement therapy. OT-58 is being developed for the treatment of classical homocystinuria (HCU). The Company's commercial products include Chenodal, Cholbam, Thiola and Thiola EC.

Contact details

3611 Valley Centre Dr, Suite 300
United States
+1 (760) 2608600

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$1.48 billion
Shares in issue:
60.24 million
United States
US dollar

Key personnel

  • Gary Lyons
    Independent Chairman of the Board
  • Eric Dube
    President, Chief Executive Officer, Director
  • Laura Clague
    Chief Financial Officer, Senior Vice President
  • Elizabeth Reed
    Senior Vice President, General Counsel and Corporate Secretary
  • William Rote
    Senior Vice President and Head of Research and Development
  • Peter Heerma
    Chief Commercial Officer
  • Noah Rosenberg
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.